65,437 trials
Pain
Primary: Plasma Area Under the Curve (AUC(0 to Infinity)) for Etoricoxib — 32.65; 33.28 µg times hr/mL
Skin Aging · Photoaging of Skin
Primary: Percent Change From Baseline in Microtopographic Profilometry Ra Values (Skin Roughness). — 3.62; 18.57 Percent change post-treatment — p=<0.0001
Dental Plaque
Primary: Plaque Index — 2.63; 2.65; 1.23 Units on a scale — p=0.05
Rectal Cancer
Primary: Pathologic Local Tumor Response — 8; 6; 11 Participants
Familial Cold Autoinflammatory Syndrome (FCAS) · Familial Cold Urticaria · Muckle-Wells Syndrome (MWS)
Primary: Change From Baseline to Week-6 (Part A) Endpoint in Mean Key Symptom Score (KSS) — 2.4; 3.1; 2.1; 0.5 Units of a Scale — p=<.0001
Diabetes Mellitus, Type 2
Primary: Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation Events — 321; 323 participants
Allergic Rhinitis
Primary: The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days — -0.64; -0.49 Units on a scale — p=0.006
Epilepsy
Primary: Assessment of Safety of Levetiracetam as Per Adverse Event (AE) Reporting in Open-label Therapy Phase — 40; 8; 1; 16 participants
Gastrointestinal Stromal Tumors
Primary: Number of Subjects With Dose Limiting Toxicities (DLT) — 0; 0; 2 participants
Chronic Hepatitis C · Hemodialysis
Primary: 1.Number of Participants With Sustained Virologic Response (SVR) 2.Number of Participants Who Droppoed Out of the Study Prematurely Due to Adverse Events (AEs) — 13; 8…
Adrenal Insufficiency
Primary: Cortisol Levels Pre and Post Rapid Sequence Induction and Cortisol Stimulation Test
Rheumatoid Arthritis
Primary: Relapse of Arthritis — 8; 13; 44; 46 participants
Melanoma
Primary: Sensitivity and Specificity — 98.2; 9.5 Ratio * 100 — p=0.05
Allergic Conjunctivitis
Primary: Ocular Comfort — 0.13; 0.07; 0.06; 0.02 Scores on a scale
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough FEV1 (Forced Expiratory Volume in 1 Second) at 12 Weeks — 0.081; -0.025 Liters — p=<0.0001